Health Daily - 14/01/2026

• The EU’s European Health Data Space (Regulation (EU) 2025/327) is standardizing cross‑border health data exchange via MyHealth@EU, enabling telemedicine to move from pilots to a regulated system across member states. 
• Real‑world deployments now cover teleconsultation, telemonitoring, teleradiology, telepathology and even cross‑border telesurgery, with chronic disease management and oncology among the most common uses. 
• Persistent barriers include divergent national liability rules, inconsistent professional qualification recognition, varied consent and data‑protection interpretations, and unclear reimbursement for cross‑border telemedicine. 
• AI is being integrated for remote monitoring, image analysis and language translation, but must comply with the EU AI Act’s high‑risk requirements, demanding transparency, human oversight and robust infrastructure. 

• OpenEvidence’s AI‑driven medical search engine is now used daily by over 40% of U.S. physicians across more than 10,000 hospitals, supporting about 18 million clinical consultations in December 2025 alone. 
• The company has secured strategic content partnerships with the AMA, NEJM, JAMA and all 11 JAMA specialty journals, and a licensing deal with NCCN to embed oncology guidelines into its platform. 
• Backed by investors such as Sequoia, GV and Mayo Clinic, OpenEvidence’s valuation rose to $6 billion in October 2025 after raising nearly $500 million since its 2022 launch. 
• Founder Daniel Nadler envisions “medical super‑intelligence” built from agentic AI sub‑specialists that can collaborate like digital twins of clinicians, a solution aimed at helping small and rural practices access expert‑level care. 

• 4DMedical, a respiratory imaging firm, launched a cash call on Jan 13 2026 to raise $150 million. 
• The offering targets a share price of $3.80, valuing the company at $2.3 billion. 
• Proceeds will be used to accelerate commercialization of its 4D imaging technology in the United States. 
• Bell Potter’s investment team is leading the ECM transaction, marking the first major health‑tech deal of 2026. 

• Kestra Medical announced a strategic collaboration with Biobeat, featuring an exclusive license, co‑development agreement, and a $5 million equity investment in Biobeat’s Series B financing. 
• Biobeat’s FDA‑cleared, cuffless, patch‑worn ABPM device uses photoplethysmography to deliver continuous 24‑hour, non‑invasive blood‑pressure readings for hypertension diagnosis and management. 
• The integration will embed Biobeat’s ABPM data into Kestra’s ASSURE Wearable Cardioverter Defibrillator, addressing the 72 % hypertension rate observed in the ACE‑PAS study of cardiac‑recovery patients. 
• The partnership aims to give clinicians real‑time blood‑pressure visibility during at‑home cardiac recovery, enhancing decision‑making and supporting guideline‑directed medical therapy optimization.